Ventyx Biosciences (NASDAQ:VTYX) Stock Rating Lowered by Wells Fargo & Company

Ventyx Biosciences (NASDAQ:VTYX) was downgraded by investment analysts at Wells Fargo & Company from a “strong-buy” rating to a “hold” rating in a report issued on Wednesday,Zacks.com reports.

VTYX has been the topic of several other reports. HC Wainwright downgraded shares of Ventyx Biosciences from a “buy” rating to a “neutral” rating and set a $14.00 target price on the stock. in a research note on Thursday. Lifesci Capital reissued a “market perform” rating and issued a $14.00 price target on shares of Ventyx Biosciences in a report on Thursday. Canaccord Genuity Group downgraded shares of Ventyx Biosciences from a “buy” rating to a “hold” rating and lowered their price objective for the company from $16.00 to $14.00 in a research note on Thursday. Piper Sandler lowered shares of Ventyx Biosciences from an “overweight” rating to a “neutral” rating and set a $14.00 target price for the company. in a report on Thursday. Finally, Clear Str cut Ventyx Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Eight investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average price target of $14.86.

Ventyx Biosciences Price Performance

Shares of VTYX stock opened at $13.81 on Wednesday. The business has a 50-day moving average of $9.27 and a 200 day moving average of $5.28. Ventyx Biosciences has a 1-year low of $0.78 and a 1-year high of $25.00. The stock has a market capitalization of $985.48 million, a PE ratio of -9.21 and a beta of 1.23.

Ventyx Biosciences (NASDAQ:VTYX) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.13. Analysts anticipate that Ventyx Biosciences will post -2.09 EPS for the current year.

Insider Transactions at Ventyx Biosciences

In other Ventyx Biosciences news, insider John Nuss sold 12,675 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total transaction of $97,851.00. Following the transaction, the insider owned 489,481 shares in the company, valued at approximately $3,778,793.32. This represents a 2.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Raju Mohan sold 47,345 shares of the stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $365,503.40. Following the completion of the transaction, the chief executive officer directly owned 2,372,863 shares of the company’s stock, valued at $18,318,502.36. This represents a 1.96% decrease in their position. The disclosure for this sale is available in the SEC filing. 14.49% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Ventyx Biosciences

Several hedge funds have recently made changes to their positions in VTYX. Affinity Asset Advisors LLC purchased a new stake in Ventyx Biosciences in the second quarter worth $9,707,000. Vanguard Group Inc. boosted its holdings in shares of Ventyx Biosciences by 19.2% during the 3rd quarter. Vanguard Group Inc. now owns 3,769,997 shares of the company’s stock valued at $11,725,000 after buying an additional 607,725 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Ventyx Biosciences in the 2nd quarter worth about $5,129,000. Vestal Point Capital LP grew its position in shares of Ventyx Biosciences by 2.5% in the 3rd quarter. Vestal Point Capital LP now owns 2,050,000 shares of the company’s stock worth $6,376,000 after buying an additional 50,000 shares during the period. Finally, Millennium Management LLC increased its stake in shares of Ventyx Biosciences by 17.5% in the 3rd quarter. Millennium Management LLC now owns 1,651,794 shares of the company’s stock worth $5,137,000 after acquiring an additional 246,040 shares in the last quarter. 97.88% of the stock is currently owned by institutional investors.

More Ventyx Biosciences News

Here are the key news stories impacting Ventyx Biosciences this week:

• Positive Sentiment: Lilly confirms definitive agreement to acquire Ventyx for $14.00 per share (≈$1.2B total), providing a clear cash exit and a floor under the stock while closing risk and timing remain uncertainties. Lilly to acquire Ventyx Biosciences
• Positive Sentiment: UBS begins coverage with a Buy rating and $20.00 price target, implying material upside from the current market level and signaling confidence in Ventyx’s assets/strategic value to acquirers. UBS coverage reported
• Neutral Sentiment: Wells Fargo reaffirmed an “equal weight” rating with a $14.00 price target — effectively in line with the acquisition price and suggesting limited near-term upside beyond the deal consideration. Wells Fargo note
• Neutral Sentiment: Lifesci Capital and Lifesci-related coverage moved to “market perform”/”hold” around the deal price, indicating analysts are treating the announced transaction as the primary valuation anchor. Lifesci/Lifesci Capital coverage
• Negative Sentiment: Several sell-side firms (Oppenheimer, Canaccord Genuity, Clear Street) issued downgrades or cut enthusiasm for VTYX after the deal — moves that can add selling pressure on any remaining float and reflect concerns about upside beyond the $14 offer. Oppenheimer downgrade Canaccord downgrade
• Negative Sentiment: Multiple law firms have launched investigations and shareholder alerts alleging possible unfair process or inadequate price in the Lilly deal; such litigation can delay closing, raise transaction costs, and add uncertainty around final shareholder recoveries. Kahn Swick & Foti investigation Edelson Lechtzin investigation

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.